Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Short Interest Down 14.5% in October

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) saw a significant decline in short interest in October. As of October 31st, there was short interest totalling 887,500 shares, a decline of 14.5% from the October 15th total of 1,038,600 shares. Based on an average daily volume of 100 shares, the days-to-cover ratio is presently 8,875.0 days.

Swedish Orphan Biovitrum AB (publ) Price Performance

Swedish Orphan Biovitrum AB (publ) stock remained flat at $31.38 during midday trading on Friday. Swedish Orphan Biovitrum AB has a 1 year low of $21.05 and a 1 year high of $32.25. The firm’s 50 day moving average price is $30.89 and its two-hundred day moving average price is $27.70. The company has a quick ratio of 0.49, a current ratio of 0.73 and a debt-to-equity ratio of 0.30.

Swedish Orphan Biovitrum AB (publ) Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.